The intracellular pharmacology of antiretroviral protease inhibitors [PDF]
Journal of Antimicrobial Chemotherapy, 2004 Therapeutic drug monitoring (TDM) of antiretroviral protease inhibitors (PIs) has been suggested to have the potential to both reduce toxicity and optimize individual therapy. However, the major target of PIs is within cells infected with HIV. Therefore clinical outcome ultimately must be related to intracellular drug concentrations since antiviral ...
J, Ford, S H, Khoo, D J, Back
openaire +2 more sources
Myricetin, the main flavonoid in Syzygium cumini leaf, is a novel inhibitor of platelet thiol isomerases PDI and ERp5 [PDF]
, 2020 Background: Flavonoids have been characterized as a prominent class of compounds to treat thrombotic diseases through the inhibition of thiol isomerases. Syzygium cumini is a flavonoid-rich medicinal plant that contains myricetin and gallic acid.
Ayyanar +45 more
core +1 more source
Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. [PDF]
, 2020 COR388, a small-molecule lysine-gingipain inhibitor, is currently being investigated in a Phase 2/3 clinical trial for Alzheimer's disease (AD) with exploratory endpoints in periodontal disease.
Arastu-Kapur, Shirin +10 more
core +1 more source
International Journal of Molecular Sciences, 2022 The action of proteases can be controlled by several mechanisms, including regulation through gene expression; post-translational modifications, such as glycosylation; zymogen activation; targeting specific compartments, such as lysosomes and mitochondria; and blocking proteolysis using endogenous inhibitors. Protease inhibitors are important molecules
Camila Ramalho Bonturi +7 more
openaire +2 more sources
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]
, 2011 In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas +30 more
core +6 more sources
G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease [PDF]
, 2015 G protein-coupled receptor 35 (GPR35) is an orphan receptor, discovered in 1998, that has garnered interest as a potential therapeutic target through its association with a range of diseases.
Amanda E Mackenzie +4 more
core +5 more sources
Personalizing HIV therapy, mission impossible? [PDF]
, 2012 Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
A brief overview of current drug repurposing approaches for COVID-19 management [PDF]
, 2020 This brief overview is intended to shed light on the current drug repositioning (also called drug repurposing) in the therapeutics of the novel coronavirus disease which emerged in 2019 (COVID-19).
Rodrigues, Pedro da Fonseca Soares +1 more
core +2 more sources
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. [PDF]
, 2016 The poor prognosis for patients with inflammatory breast cancer (IBC) compared to patients with other types of breast cancers emphasizes the need to better understand the molecular underpinnings of this disease with the goal of developing effective ...
Boerner, Julie +11 more
core +2 more sources